Skip to main content

Small Pharma Inc(DMT-X)
TSX Venture

Today's Change
Real-Time Last Update

U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation

Globe Newswire - Tue Jul 26, 2022

Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028

LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received Issue Notification from the United States Patent and Trademark Office that its patent application no. 17/459,284 will be granted on August 9, 2022 in the United States under patent no. 11,406,619 for novel injectable formulations of N,N-dimethyltryptamine (“DMT”) based compounds. The patent, which will represent the Company’s ninth issued patent, will be the first U.S. patent grant within the Company’s psychedelic portfolio, and includes formulations of DMT, the active ingredient in SPL026, and of deuterium-substituted DMT, including the active ingredient in SPL028. The patent will also protect novel injectable formulations of other known psychedelic compounds, including 5-methoxy-DMT and psilocybin.


Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.